Comparison between calcitriol and calcitriol plus low-dose cinacalcet for the treatment of moderate to severe secondary hyperparathyroidism in chronic dialysis patients.

Uremic hyperparathyroidism (UHPT) has been shown to contribute to the development and progression of chronic kidney disease-mineral bone disorder. UHPT is frequently observed in chronic dialysis patients, and patients with UHPT are associated with increased risk of all-cause and cardiovascular mortality. Cinacalcet is a novel agent that increases sensitivity to the calcium-sensing receptor and is approved for control of UHPT. Nevertheless, cinacalcet is costly and information regarding efficacy of low-dose cinacalcet on UHPT is limited.
We conducted a retrospective study to evaluate treatment with either low-dose calcitriol combined with low-dose cinacalcet (25 mg) (d-cinacalcet) or calcitriol alone (VitD) in dialysis patients with moderate to severe UHPT. A total of 81 dialysis patients were enrolled (40 subjects in d-cinacalcet group and 41 subjects in VitD group). Demographic data including age, gender, duration on dialysis and biochemical data were reviewed and recorded.
At the end of the study, the intact parathyroid hormone (iPTH) levels of the d-cinacalcet group declined significantly (from 1166.0 ± 469.3 pg/mL to 679.8 ± 421.6 pg/mL, p < 0.0001), while there was no significant change in the VitD group. Significant decrease of serum calcium (Ca: 9.9 ± 0.6 mg/dL vs. 9.6 ± 0.8 mg/dL, p = 0.002), phosphorus (P: 5.9 ± 1.3 mg/dL vs. 4.9 ± 0.9 mg/dL, p < 0.0001) and calcium phosphate product (Ca × P: 58.7 ± 15.0 mg2/dL2 vs. 46.9 ± 8.9 mg2/dL2, p < 0.0001) were observed in the d-cinacalcet group. In addition, the subjects in the d-cinacalcet group had a greater proportion to achieve Kidney Disease Outcomes Quality Initiative (KDOQI)-recommended biochemical targets than the subjects in the VitD group (Ca: 48% vs. 24%; P: 78% vs. 32%; Ca × P: 85% vs. 37%; iPTH: 15% vs. 0%).
We conclude that combination therapy of low-dose cinacalcet and calcitriol is more effective than calcitriol alone as a treatment for moderate and severe UHPT in chronic dialysis patients. Furthermore, this therapy is associated with improvement in hyperphosphatemia and hypercalcemia.
AuthorsYueh-Ting Lee, Hwee-Yeong Ng, Chien-Chun Kuo, Te-Chuan Chen, Chien-Shing Wu, Terry Ting-Yu Chiu, Wen-Chin Lee, Chien-Te Lee
JournalNutrients (Nutrients) Vol. 5 Issue 4 Pg. 1336-48 (Apr 2013) ISSN: 2072-6643 [Electronic] Switzerland
PMID23603995 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Biomarkers
  • Calcimimetic Agents
  • Naphthalenes
  • PTH protein, human
  • Parathyroid Hormone
  • Phosphates
  • Vitamins
  • Cinacalcet Hydrochloride
  • Calcitriol
  • Calcium
  • Adult
  • Aged
  • Biomarkers (blood)
  • Calcimimetic Agents (administration & dosage)
  • Calcitriol (therapeutic use)
  • Calcium (blood)
  • Cinacalcet Hydrochloride
  • Drug Therapy, Combination
  • Female
  • Guideline Adherence
  • Humans
  • Hyperparathyroidism, Secondary (blood, diagnosis, drug therapy, etiology)
  • Male
  • Middle Aged
  • Naphthalenes (administration & dosage)
  • Parathyroid Hormone (blood)
  • Phosphates (blood)
  • Practice Guidelines as Topic
  • Renal Dialysis (adverse effects)
  • Renal Insufficiency, Chronic (complications, therapy)
  • Retrospective Studies
  • Severity of Illness Index
  • Treatment Outcome
  • Uremia (etiology)
  • Vitamins (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: